Iqvia Holdings earnings release, July 28, 2026

Iqvia Holdings Inc. (IQV) · Form 8-K, Item 2.02 · Filed · SEC filing

IQVIA Reports Second-Quarter 2026 Results

• Revenue $4,368 million, up 8.7% year-over-year

• GAAP Net Income $256 million, Adjusted EBITDA $994 million, up 9.2% year-over-year

• GAAP Diluted Earnings per Share $1.53, Adjusted Diluted Earnings per Share $3.15, up 12.1% year-over-year

• Commercial Solutions Revenue $1,793 million, up 8.6% year-over-year

• R&D Solutions Revenue $2,575 million, up 8.8% year-over-year

• R&D Solutions Net New Bookings $3.15 billion, up 19% year-over-year, 1.22x book-to-bill ratio

• Operating Cash Flow $558 million, up 26.0% year-over-year, and Free Cash Flow $360 million, up 23.3% year-over-year

• Raising full-year 2026 guidance for Revenue, Adjusted EBITDA and Adjusted Diluted Earnings per Share

RESEARCH TRIANGLE PARK, N.C. – (BUSINESS WIRE) – July 28, 2026 – IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today reported financial results for the quarter ended June 30, 2026.

Year-Over-Year Comparisons

As previously disclosed, effective January 1, 2026, the company implemented a new, simplified organizational model to strengthen collaboration, enhance efficiency, and support continued growth. As a result, the company reports its results within two segments: Commercial Solutions and Research & Development Solutions (R&DS). In conjunction with this change, prior period segment amounts have been recast to conform to this reporting structure.

Second-Quarter 2026 Operating Results

"In a strengthening market environment, the IQVIA team executed well and delivered outstanding results, exceeding the high-end of our expectations for revenue, Adjusted EBITDA and Adjusted Diluted EPS," said Ari Bousbib, chairman and CEO of IQVIA. "R&D Solutions generated record-level net new bookings of over $3.1 billion and reported 7% organic revenue growth. In Commercial Solutions, double digit growth in patient solutions and commercial engagement services, high-single-digit organic growth in analytics and consulting, and increased adoption of our AI solutions all contributed to strong acceleration of organic revenue growth year-over-year. This excellent operational performance combined with favorable forward-looking indicators across both segments point to sustained momentum for the balance of the year and into 2027."

Revenue for the second quarter of $4,368 million increased 8.7% on a reported basis and 8.5% at constant currency, compared to the second quarter of 2025. Commercial Solutions revenue of $1,793 million increased 8.6% on a reported basis and 8.4% at constant currency. Research & Development Solutions revenue of $2,575 million grew 8.8% on a reported basis and 8.6% at constant currency. Excluding reimbursed expenses, R&DS revenue grew 6.7% on a reported basis.

Second quarter net new bookings were $3.15 billion, an increase of 19% year-over-year, resulting in a book-to-bill ratio of 1.22x. The last-twelve months net new bookings were $11.3 billion, up 13% year-over-year. As of June 30, 2026, R&DS contracted backlog was $34.2 billion. The company expects approximately $9.2 billion of this backlog to convert to revenue in the next twelve months, representing growth of 7.5% year-over-year.

Second-quarter GAAP Net Income was $256 million and GAAP Diluted Earnings per Share was $1.53. Adjusted EBITDA was $994 million, up 9.2% year-over-year. Adjusted Net Income was $527 million and Adjusted Diluted Earnings per Share was $3.15, up 12.1% year-over-year.¹

First-Half 2026 Operating Results

Revenue for the first six months of 2026 was $8,519 million, up 8.6% on a reported basis and 7.3% at constant currency, compared to the first six months of 2025. Commercial Solutions revenue of $3,547 million increased 10.1% on a reported basis and 8.5% at constant currency. Research & Development Solutions revenue of $4,972 million increased 7.5% on a reported basis and 6.4% at constant currency.

GAAP Net Income was $530 million and GAAP Diluted Earnings per Share was $3.14. Adjusted EBITDA was $1,926 million, up 7.4% year-over-year. Adjusted Net Income was $1,019 million and Adjusted Diluted Earnings per Share was $6.04, up 9.8% year-over-year.

Financial Position

As of June 30, 2026, cash and cash equivalents were $1,909 million and debt was $15,999 million, resulting in net debt of $14,090 million. IQVIA’s Net Leverage Ratio was 3.59x trailing twelve-month Adjusted EBITDA. For the second quarter, Operating Cash Flow was $558 million, up 26.0% year-over-year, and Free Cash Flow was $360 million, up 23.3% year-over-year.

Share Repurchase

During the second quarter of 2026, the company repurchased $398 million of its common stock, resulting in first-half share repurchases of $950 million. IQVIA had $2,819 million of share repurchase authorization remaining as of June 30, 2026.

Full-Year 2026 Guidance

To reflect stronger organic revenue growth, and changes in the M&A and foreign exchange impacts, the company is raising its full-year 2026 guidance for revenue to be between $17,275 million and $17,475 million, for Adjusted EBITDA to be between $4,000 million and $4,050 million and for Adjusted Diluted Earnings per Share to be between $12.80 and $13.00.

The new mid-point of the revenue growth guidance is 6.5% versus the prior guidance of 5.8%, reflecting approximately 100 basis points higher organic revenue growth, and approximately 50 basis points higher contribution from M&A offset by approximately 80 basis points unfavorable change in foreign exchange impact, all versus prior guidance.... (truncated), 2026 remain in effect for the forecast period.

Webcast & Conference Call Details

IQVIA will host a conference call at 9:00 a.m. Eastern Time today to discuss its second-quarter 2026 results and its third-quarter and full-year 2026 guidance. To listen to the event and view the presentation slides via webcast, join from the IQVIA Investor Relations website at http://ir.iqvia.com. To participate in the conference call, interested parties must register in advance by clicking on this link. Following registration, participants will receive a confirmation email containing details on how to join the conference call, including the dial-in and a unique passcode and registrant ID. At the time of the live event, registered participants connect to the call using the information provided in the confirmation email and will be placed directly into the call.²

About IQVIA

IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI®, advanced analytics, the latest technologies and extensive domain expertise. IQVIA is committed to using artificial intelligence responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 94,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.³

Financial statements

Income Statement

Three Months Ended June 30, — (preliminary and unaudited) (in millions, except per share data)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Revenues4,3684,0178,5197,846
Cost of revenues, exclusive of depreciation and amortization2,9332,6945,7295,225
Selling, general and administrative expenses5745091,0761,017
Depreciation and amortization292276580541
Restructuring costs633211461
Income from operations5065061,0201,002
Interest income-7-10-17-21
Interest expense197182389347
Loss on extinguishment of debt334
Other expense, net12111626
Income before income taxes and equity in earnings (losses) of unconsolidated affiliates301323629646
Income tax expense6056119117
Income before equity in earnings (losses) of unconsolidated affiliates241267510529
Equity in earnings (losses) of unconsolidated affiliates17-123-14
Net income258266533515
Net income attributable to noncontrolling interests-2-3
Net income attributable to IQVIA Holdings Inc.256266530515
Earnings per share attributable to common stockholders:Basic1.541.553.172.96
Earnings per share attributable to common stockholders:Diluted1.531.543.142.94
Weighted average common shares outstanding:Basic166.1171.8167.2173.7
Weighted average common shares outstanding:Diluted167.3173.2168.6175.3

Income Statement

Three Months Ended June 30, — (preliminary and unaudited) (in millions)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Net Income Attributable to IQVIA Holdings Inc.256266530515
Provision for income taxes6056119117
Depreciation and amortization292276580541
Interest expense, net190172372326
(Income) loss in unconsolidated affiliates-171-2314
Income from noncontrolling interests23
Stock-based compensation9560160132
Other expense, net (1)36294144
Loss on extinguishment of debt334
Restructuring and related expenses (2)674212084
Acquisition related expenses1082116
Adjusted EBITDA9949101,9261,793

Income Statement

Three Months Ended June 30, — (preliminary and unaudited) (in millions, except per share data)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Net Income Attributable to IQVIA Holdings Inc.256266530515
Provision for income taxes6056119117
Purchase accounting amortization (1)136131273256
(Income) loss in unconsolidated affiliates-171-2314
Income from noncontrolling interests23
Stock-based compensation9560160132
Other expense, net (2)36294144
Loss on extinguishment of debt334
Restructuring and related expenses (3)674212084
Acquisition related expenses1082116
Adjusted Pre Tax Income6485931,2471,182
Adjusted tax expense-119-107-225-217
Income from noncontrolling interests-2-3
Adjusted Net Income5274861,019965
Adjusted earnings per share attributable to common stockholders:Basic3.172.836.095.56
Adjusted earnings per share attributable to common stockholders:Diluted3.152.816.045.5
Weighted average common shares outstanding:Basic166.1171.8167.2173.7
Weighted average common shares outstanding:Diluted167.3173.2168.6175.3

Balance Sheet

June 30, 2026 — (preliminary and unaudited) (in millions, except per share data)

June 30, 2026December 31, 2025
Cash and cash equivalents1,9091,980
Trade accounts receivable and unbilled services, net3,3453,400
Prepaid expenses220162
Income taxes receivable4227
Investments in debt, equity and other securities171161
Other current assets and receivables539519
Total current assets6,2266,249
Property and equipment, net547533
Operating lease right-of-use assets304290
Investments in debt, equity and other securities82108
Investments in unconsolidated affiliates390324
Goodwill16,60416,616
Other identifiable intangibles, net4,7494,962
Deferred income taxes421357
Deposits and other assets, net558505
Total assets29,88129,944
Current liabilities:Accounts payable and accrued expenses3,6083,751
Current liabilities:Unearned income2,2812,118
Current liabilities:Income taxes payable175140
Current liabilities:Current portion of long-term debt2,2941,840
Current liabilities:Other current liabilities457489
Current liabilities:Total current liabilities8,8158,338
Current liabilities:Long-term debt, less current portion13,70513,884
Current liabilities:Deferred income taxes173179
Current liabilities:Operating lease liabilities242225
Current liabilities:Other liabilities645688
Current liabilities:Total liabilities23,58023,314
Stockholders’ equity:Common stock and additional paid-in capital, 400.0 shares authorized as of June 30, 2026 and December 31, 2025, $0.01 par value, 259.6 shares issued and 164.6 shares outstanding as of June 30, 2026; 259.1 shares issued and 169.6 shares outstanding as of December 31, 202511,49611,378
Stockholders’ equity:Retained earnings7,9557,425
Stockholders’ equity:Treasury stock, at cost, 95.0 and 89.5 shares as of June 30, 2026 and December 31, 2025, respectively-12,316-11,357

Cash Flow

Six Months Ended June 30, — (preliminary and unaudited) (in millions)

Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Net income533515
Adjustments to reconcile net income to cash provided by operating activities:Depreciation and amortization580541
Adjustments to reconcile net income to cash provided by operating activities:Amortization of debt issuance costs and discount1211
Adjustments to reconcile net income to cash provided by operating activities:Stock-based compensation160132
Adjustments to reconcile net income to cash provided by operating activities:(Earnings) losses from unconsolidated affiliates-2314
Adjustments to reconcile net income to cash provided by operating activities:Loss (gain) on investments, net12-16
Adjustments to reconcile net income to cash provided by operating activities:Benefit from deferred income taxes-74-86
Changes in operating assets and liabilities:Change in accounts receivable, unbilled services and unearned income239269
Changes in operating assets and liabilities:Change in other operating assets and liabilities-263-369
Changes in operating assets and liabilities:Net cash provided by operating activities1,1761,011
Investing activities:Acquisition of property, equipment and software-325-293
Investing activities:Acquisition of businesses, net of cash acquired-200-315
Investing activities:Sales of marketable securities, net32
Investing activities:Investments in unconsolidated affiliates, net of payments received-58-27
Investing activities:Investments in debt and equity securities-19
Investing activities:Other31
Investing activities:Net cash used in investing activities-577-651
Financing activities:Proceeds from issuance of debt1,7583,985
Financing activities:Payment of debt issuance costs-20-35
Financing activities:Repayment of debt and principal payments on finance leases-1,370-2,140
Financing activities:Proceeds from revolving credit facility900875
Financing activities:Repayment of revolving credit facility-900-1,700
Financing activities:Payments related to employee stock incentive plans-41-35
Financing activities:Repurchase of common stock-950-1,032
Financing activities:Contingent consideration and deferred purchase price payments-15-20
Financing activities:Other-9-11
Financing activities:Net cash used in financing activities-647-113
Financing activities:Effect of foreign currency exchange rate changes on cash-2390
Financing activities:(Decrease) increase in cash and cash equivalents-71337
Financing activities:Cash and cash equivalents at beginning of period1,9801,702
Financing activities:Cash and cash equivalents at end of period1,9092,039

Cash Flow

Three Months Ended June 30, — (preliminary and unaudited) (in millions)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Net Cash provided by Operating Activities5584431,1761,011
Acquisition of property, equipment and software-198-151-325-293
Free Cash Flow360292851718
Full release

Cautionary Statements Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, without limitation, our full-year 2026 guidance. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as “expect,” “assume,” “anticipate,” “intend,” “plan,” “forecast,” “believe,” “seek,” “see,” “will,” “would,” “target,” similar expressions, and variations or negatives of these words that are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from our expectations due to a number of factors, including, but not limited to, the following: business disruptions caused by natural disasters, pandemics, and the public health policy response to any outbreak, and international conflicts or other disruptions outside of our control; most of our contracts may be terminated on short notice, and we may lose or experience delays with large client contracts or be unable to enter into new contracts; the market for our services may not grow as we expect; we may be unable to successfully develop and market new services or enter new markets; imposition of restrictions on our use of data by data suppliers or their refusal to license data to us; any failure by us to comply with contractual, regulatory or ethical requirements under our contracts, including current or future changes to data protection and privacy laws; breaches or misuse of our or our outsourcing partners’ security or communications systems; failure to meet our productivity or business transformation objectives; failure to successfully invest in growth opportunities; our ability to protect our intellectual property rights and our susceptibility to claims by others that we are infringing on their intellectual property rights; the expiration or inability to acquire third party licenses for technology or intellectual property; any failure by us to accurately and timely price and formulate cost estimates for contracts, or to document change orders; hardware and software failures, delays in the operation of our computer and communications systems or the failure to implement system enhancements; the rate at which our backlog converts to revenue; our ability to acquire, develop and implement technology necessary for our business; consolidation in the industries in which our clients operate; risks related to client or therapeutic concentration; government regulators or our customers may limit the number or scope of indications for medicines and treatments or withdraw products from the market, and government regulators may impose new regulatory requirements or may adopt new regulations affecting the biopharmaceutical industry; the risks associated with operating on a global basis, including currency or exchange rate fluctuations and legal compliance, including anti-corruption laws; risks related to the enactment of legislation or the imposition of regulations or other restrictions or actions by governments that create business uncertainty and have the potential to limit trade; changes in accounting standards; general economic conditions in the markets in which we operate, including financial market conditions, inflation, and risks related to sales to government entities; the impact of changes in tax laws and regulations; and our ability to successfully integrate, and achieve expected benefits from, our acquired businesses. In addition, we may not achieve the expected benefits of our reorganized business segment structure.

For a further discussion of the risks relating to our business, see the “Risk Factors” in our annual report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission (the "SEC"), as such factors may be amended or updated from time to time in our subsequent periodic and other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this release and in our filings with the SEC. We assume no obligation to update any such forward-looking statement after the date of this release, whether as a result of new information, future developments or otherwise.⁴

Note on Non-GAAP Financial Measures

This release includes information based on financial measures that are not recognized under generally accepted accounting principles in the United States ("GAAP"), such as Adjusted EBITDA, Adjusted Net Income, Adjusted Diluted Earnings per Share, Gross Leverage Ratio, Net Leverage Ratio and Free Cash Flow. Non-GAAP financial measures are presented only as a supplement to the company’s financial statements based on GAAP. Non-GAAP financial information is provided to enhance understanding of the company’s financial performance, but none of these non-GAAP financial measures are recognized terms under GAAP, and non-GAAP measures should not be considered in isolation from, or as a substitute analysis for, the company’s results of operations as determined in accordance with GAAP. The company uses non-GAAP measures in its operational and financial decision making, and believes that it is useful to exclude certain items in order to focus on what it regards to be a more meaningful indicator of the underlying operating performance of the business. For example, the company excludes all the amortization of intangible assets associated with acquired customer relationships and backlog, databases, non-compete agreements, trademarks and trade names from non-GAAP expense and income measures as such amounts can be significantly impacted by the timing and size of acquisitions. Although we exclude amortization of acquired intangible assets from our non-GAAP expenses, we believe that it is important for investors to understand that revenue generated from such intangibles is included within revenue in determining net income. As a result, internal management reports feature non-GAAP measures which are also used to prepare strategic plans and annual budgets and review management compensation. The company also believes that investors may find non-GAAP financial measures useful for the same reasons, although investors are cautioned that non-GAAP financial measures are not a substitute for GAAP disclosures.

The non-GAAP financial measures are not presented in accordance with GAAP. Please refer to the schedules attached to this release for reconciliations of non-GAAP financial measures contained herein to the most directly comparable GAAP measures. Our full-year 2026 guidance measures (other than revenue) are provided on a non-GAAP basis without a reconciliation to the most directly comparable GAAP measure because the company is unable to predict with a reasonable degree of certainty certain items contained in the GAAP measures without unreasonable efforts. For the same reasons, the company is unable to address the probable significance of the unavailable information. Such items include, but are not limited to, acquisition related expenses, restructuring and related expenses, stock-based compensation and other items not reflective of the company's ongoing operations.

Non-GAAP measures are frequently used by securities analysts, investors and other interested parties in their evaluation of companies comparable to the company, many of which present non-GAAP measures when reporting their results. Non-GAAP measures have limitations as an analytical tool. They are not presentations made in accordance with GAAP, are not measures of financial condition or liquidity and should not be considered as an alternative to profit or loss for the period determined in accordance with GAAP or operating cash flows determined in accordance with GAAP. Non-GAAP measures are not necessarily comparable to similarly titled measures used by other companies. As a result, you should not consider such performance measures in isolation from, or as a substitute analysis for, the company’s results of operations as determined in accordance with GAAP.

IQVIAFIN

#

#

#⁵

Table 1

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Iqvia Holdings earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.